# EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease

> **NCT07168603** · PHASE1,PHASE2 · RECRUITING · sponsor: **ASTEROGENE Biomedical Co. Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Intervertebral Disc Degeneration

## Interventions

- **DRUG:** aNPC

## Key facts

- **NCT ID:** NCT07168603
- **Lead sponsor:** ASTEROGENE Biomedical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168603, "EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07168603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*